Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Protara Therapeutics Inc. TARA

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).


Recent & Breaking News (NDAQ:TARA)

Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

GlobeNewswire September 22, 2020

Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

GlobeNewswire September 21, 2020

Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications

GlobeNewswire September 8, 2020

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 2, 2020

Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview

GlobeNewswire August 3, 2020

Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations

GlobeNewswire July 28, 2020

Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors

GlobeNewswire July 24, 2020

CORRECTION - Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 2, 2020

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 2, 2020

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 2, 2020

Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease

GlobeNewswire May 26, 2020

Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview

GlobeNewswire May 13, 2020

ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics

GlobeNewswire May 11, 2020

ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 5, 2020

ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 2, 2020

ArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer

GlobeNewswire February 11, 2020

ArTara Therapeutics Completes Merger Transaction with Proteon Therapeutics

GlobeNewswire January 9, 2020

Rigrodsky & Long, P.A. Files Class Action Suit Against Proteon Therapeutics, Inc.

GlobeNewswire December 5, 2019

Moore Kuehn, PLLC Encourages Liberty Property Trust (LPT), Proteon Therapeutics (PRTO), Ra Pharmaceuticals (RARX), Carolina Trust BancShares (CART), and Highlands Bankshares (HLND) Investors to Contact Firm

PR Newswire December 3, 2019

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

GlobeNewswire November 22, 2019